Tetsu Watanabe Selected Research

Fatty Acid Binding Protein 3

2/2018	Gender differences in the impact of anemia on subclinical myocardial damage and cardiovascular mortality in the general population: The Yamagata (Takahata) study.
1/2018	Ventricular wall stress and silent myocardial damage are associated with pulse pressure in the general population.
11/2017	Heart-type fatty acid-binding protein in cardiovascular disease: A systemic review.
5/2017	Combined assessment of myocardial damage and electrical disturbance in chronic heart failure.
3/2016	Circulating heart-type fatty acid-binding protein levels predict ventricular fibrillation in Brugada syndrome.
12/2015	Heart-type fatty acid binding protein and high-sensitivity troponin T are myocardial damage markers that could predict adverse clinical outcomes in patients with peripheral artery disease.
1/2014	Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study.
7/2012	Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
1/2012	Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.
11/2008	Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tetsu Watanabe Research Topics

Disease

31	Heart Failure 11/2022 - 02/2007
29	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 05/2006
9	Myocardial Infarction 10/2022 - 01/2013
8	Stroke (Strokes) 01/2022 - 02/2005
8	Peripheral Arterial Disease 01/2020 - 01/2015
7	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2016 - 09/2003
7	Hypertension (High Blood Pressure) 01/2015 - 09/2003
6	Inflammation (Inflammations) 11/2022 - 04/2007
6	Cardiomegaly (Heart Hypertrophy) 12/2020 - 02/2005
6	Atrial Fibrillation 01/2016 - 03/2005
5	Death (Near-Death Experience) 07/2022 - 04/2007
5	Albuminuria 08/2016 - 10/2009
5	Coronary Artery Disease (Coronary Atherosclerosis) 08/2016 - 04/2007
5	Obesity 01/2015 - 09/2003
4	Insulin Resistance 08/2016 - 04/2007
4	Chronic Hepatitis C 01/2010 - 05/2002
3	Coronary Vasospasm (Coronary Artery Vasospasm) 11/2021 - 01/2011
3	Hypertrophy 12/2020 - 09/2013
3	Hypoxia (Hypoxemia) 01/2020 - 01/2011
3	Acute Coronary Syndrome 11/2019 - 09/2014
3	Anemia 01/2019 - 05/2014
3	Diabetes Mellitus 11/2018 - 01/2014
3	Proteinuria 10/2016 - 01/2013
3	Renal Insufficiency (Renal Failure) 05/2016 - 07/2011
3	Body Weight (Weight, Body) 02/2014 - 10/2009
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2011 - 05/2002
3	Fibrosis (Cirrhosis) 01/2011 - 10/2003
3	Hepatocellular Carcinoma (Hepatoma) 08/2010 - 05/2002
3	Neoplasms (Cancer) 03/2010 - 05/2002
2	Malnutrition (Nutritional Deficiencies) 11/2022 - 01/2018
2	Disease Progression 05/2022 - 01/2011
2	Heart Diseases (Heart Disease) 06/2021 - 02/2017
2	Coronary Stenosis (Coronary Artery Stenosis) 03/2021 - 01/2019
2	Vascular Remodeling 01/2020 - 02/2005
2	Myocardial Ischemia (Ischemic Heart Diseases) 11/2018 - 01/2018
2	Cardiac Sudden Death (Sudden Cardiac Arrest) 07/2018 - 01/2011
2	Atherosclerosis 01/2018 - 01/2016
2	Stable Angina 12/2017 - 09/2014
2	Cardiac Arrhythmias (Arrythmia) 11/2017 - 03/2016
2	Chronic Limb-Threatening Ischemia 02/2017 - 12/2015
2	Shock 12/2016 - 03/2016
2	Chronic Renal Insufficiency 05/2016 - 01/2011
2	Ventricular Tachycardia 05/2016 - 12/2010
2	Ischemia 04/2016 - 01/2014
2	Heart Injuries 03/2016 - 07/2012
2	Cardiotoxicity 01/2016 - 05/2015
2	Cardiomyopathies (Cardiomyopathy) 05/2015 - 07/2012
2	Sarcopenia 03/2015 - 01/2015
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 04/2013 - 09/2008

Drug/Important Bio-Agent (IBA)

14	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2022 - 02/2007
13	Fatty Acid Binding Protein 3IBA 02/2018 - 02/2007
9	CreatinineIBA 02/2020 - 04/2007
8	Fatty Acid-Binding ProteinsIBA 02/2018 - 03/2007
7	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2008
7	Proteins (Proteins, Gene)FDA Link 12/2020 - 10/2009
5	AlbuminsIBA 11/2022 - 10/2009
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 07/2011
5	Troponin T (Troponin T1)IBA 07/2019 - 03/2007
5	CollagenIBA 02/2017 - 10/2003
5	Uric Acid (Urate)IBA 12/2016 - 05/2006
5	EnzymesIBA 07/2011 - 09/2003
4	Xanthine DehydrogenaseIBA 11/2021 - 02/2017
4	MidkineIBA 01/2020 - 04/2010
4	Alanine Transaminase (SGPT)IBA 01/2016 - 09/2003
4	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2011 - 10/2003
3	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2021 - 01/2016
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 06/2021 - 01/2016
3	UbiquitinIBA 06/2021 - 01/2016
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 01/2014
3	pro-brain natriuretic peptide (1-76)IBA 07/2019 - 05/2015
3	LipidsIBA 12/2017 - 01/2011
3	Cystatin CIBA 10/2016 - 01/2011
3	Messenger RNA (mRNA)IBA 01/2016 - 12/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 07/2011
3	SodiumIBA 01/2015 - 10/2009
3	InterferonsIBA 01/2010 - 05/2002
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2013
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 05/2016
2	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2019 - 12/2010
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2017 - 09/2014
2	Collagen Type I (Type I Collagen)IBA 02/2017 - 06/2007
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 02/2017 - 04/2007
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 05/2015
2	ThioredoxinsIBA 01/2016 - 11/2014
2	Interleukin-6 (Interleukin 6)IBA 01/2016 - 12/2011
2	HMGB1 Protein (HMG1)IBA 05/2015 - 09/2013
2	Indicators and Reagents (Reagents)IBA 03/2015 - 04/2013
2	Antihypertensive Agents (Antihypertensives)IBA 01/2015 - 07/2011
2	Pregnancy-Associated Plasma Protein-A (PAPP-A)IBA 01/2015 - 10/2011
2	AdipokinesIBA 05/2014 - 04/2014
2	AdiponectinIBA 05/2014 - 01/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2013 - 12/2012
2	Triglycerides (Triacylglycerol)IBA 04/2013 - 01/2013
2	Adenosine Triphosphate (ATP)IBA 04/2013 - 01/2011

Therapy/Procedure

16	Therapeutics 03/2021 - 05/2002
7	Patient Readmission 11/2022 - 04/2007
7	Percutaneous Coronary Intervention 10/2022 - 01/2013
5	Catheter Ablation 05/2016 - 12/2010
4	Secondary Prevention 12/2017 - 05/2012
4	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 12/2016 - 01/2011